Contract Services Clinical Research

Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

 September 04, 2026 | News

IDT and Ansa Expand Global Access to Complex DNA Synthesis Through Integrated Ordering

Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options Global adoption growing with more than 400...

 September 03, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

 September 03, 2026 | News

Singapore Becomes First ASEAN Market to Subsidise Vutrisiran for ATTR Amyloidosis

"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong ...

 September 02, 2026 | News

Thermo Fisher Launches EMPAD G2 Detector to Advance High-Speed 4D STEM Imaging

Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector design...

 August 28, 2026 | News

HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial

First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple m...

 August 27, 2026 | News

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

 August 26, 2026 | News

Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1

Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...

 August 24, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

 August 24, 2026 | News

US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging

 NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food ...

 August 21, 2026 | News

Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that its shares have begun t...

 August 21, 2026 | News

OncoC4 Doses First Patient in Phase I Trial of neoCD24-Targeting T-Cell Engager ONC-783

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous f...

 August 19, 2026 | News

AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...

 August 18, 2026 | News

Kyowa Kirin Taps Cognizant and Benchling to Build AI-Powered Drug Discovery Foundation in Japan

Cognizant announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Rese...

 August 18, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close